At DSM Biomedical, our vision of solving our world's healthcare needs through sustainable science rests upon our ambition to improve the health of people and the planet. As unrivaled experts in biomaterial science and committed partners driving sustainable innovation in healthcare, we realize our global vision by executing upstream to our suppliers, within our own operations, and downstream to our customers.
Our belief in sustainability as our core value, key responsibility, and important business driver is reflected in the recognition we receive in Environmental, Social, Governance (ESG) ratings and benchmarks.
The ESG ratings and benchmarks universe is experiencing rapid expansion and fragmentation with the World Business Council for Sustainable Development (WBCSD) reporting that there are over 2,000 individual ESG reporting indicators requested by the approximately 600 ratings and benchmarks.
There are considerable differences in stakeholder focus and approach with some concentrating on management and strategy and others on performance and metrics. It is not possible for us to actively participate in every benchmark and rating so we prioritize our participation in those that are most useful to us and our stakeholders, specifically:
DSM takes part in a number of ESG ratings but the most relevant to DSM Biomedical are the Carbon Disclosure Project (CDP) and EcoVadis.
In December 2021, for our climate strategy, and water governance and strategy in 2021, we were assessed as double A by CDP.
In September 2021, EcoVadis awarded DSM a Platinum CSR Rating. The Platinum rating places us in the top 1% of companies assessed in our industry.
In January 2022, DSM was assessed by Sustainalytics regarding the risk of experiencing material financial impacts from ESG factors, ranking in the top 4th percentile in our industry.
In October 2021, MSCI’s rating of DSM remained unchanged at ‘AAA’. The report noted a lower water risk, our carbon emission reduction efforts and our program on product stewardship.
In April 2021, ISS ESG reconfirmed DSM as ‘Prime’ according to its rating methodology. Our rating of B- puts us in the top decile relative to our industry group.
DSM’s ISS QualityScore is a low-risk rating, including lowest risk (1 out of 10) in Governance and Environment.
DSM is a constituent of the Vigeo Eiris Benelux 20, Europe 120, Eurozone 120 and World 120 indices, based on the review performed in October 2017. Koninklijke DSM has been reconfirmed as a constituent of the Ethibel Sustainability Index (ESI) Excellence Europe and the Ethibel Sustainability Index (ESI) Excellence Global since 22 March 2019.
In 2021, DSM was again confirmed as a constituent of the FTSE4Good Index. We have been listed on this index since 2004.
Our Safe and Sustainable by Design process enables us to proactively support and collaborate with our partners to design for sustainability.
We have embedded this design guidance into our project management procedures to methodically drive sustainability into our projects, as described in the graphical representation below.
For more information on how we can support you on your sustainable design journey, please get in touch with our team!
We believe so strongly in sustainability that the UN’s Sustainable Development Goals are now woven into our strategy.
At DSM, we strongly believe in doing well by doing good, which is why our company’s strategies are aligned with the UN’s Sustainable Development Goals (SDGs). As DSM Biomedical, we specifically use the four Sustainable Development Goals shown below to drive our business strategy.
Reach out to us using the contact us button below and our sustainability team will be in touch with you shortly!